TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

Benzinga Newsdesk www.benzinga.com Positive 79.5%

Neg 0% Neu 0% Pos 79.5%

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.